5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The market is segmented by Type of CNS Biomarkers (Safety Biomarker, Efficacy Biomarker, and Validation Biomarker), Application, End-User and Geography
Fastest Growing Market:
The global central nervous system biomarkers market is expected to register a CAGR of 12.5% over the forecast period. A biomarker is used to measure the biological state, presence of diseases and effects of treatments. With the advent of proteomics and genomics, the demand for central nervous system (CNS) biomarkers has increased. Due to rapid advancements in genomic technologies, genetics analyses have become essential in clinical practices and research. Moreover, with the advancement in technology, the CNS biomarker testing has become widely accessible and feasible, to perform even in small size laboratories. Certain CNS diseases are hereditary, which encouraged the search for common variant genes associated with nerve function and CNS disease phenotypes using genomic technologies. Furthermore, advanced imaging systems are aiding early diagnosis of various diseases, while reducing the mortality rate. Hence, the market studied is expected to witness steady growth over the forecast period, due to the development in proteomics, genomics, and imaging system.
As per the scope of the report, Central nervous system (CNS) biomarkers are used clinically to screen for, to diagnose, or monitor the activity of CNS-related diseases, in order to guide molecularly targeted therapy or assess therapeutic response.
|By Type of CNS Biomarkers|
|Drug Discovery & Development|
|By End User|
Report scope can be customized per your requirements. Click here.
Based on application, it is segmented into drug discovery & development, personalized medicine, and others. Precision medicine, also commonly referred to as personalized medicine, is one of the most promising approaches to tackle diseases. The key factor contributing to the growth of the segment is the rising number of brain and other nervous system cancers. Many companies are focusing on developing breakthrough products for the treatment of neurological disease. In addition, to support the advancement of precision medicine in chronic diseases, the former President of the United States, Barrack Obama announced the Precision Medicine Initiative (PMI) in 2015. The PMI was awarded USD 215 million investment in 2016, primarily aimed at accelerating biomedical research while providing clinicians with new tools and therapies for selecting biomarkers that will work best for individual patients. Hence, with the various government initiatives and wide applications of biomarkers in personalized medicine, the market is expected to grow better over the forecast period.
To understand key trends, Download Sample Report
The Central Nervous System Biomarkers market holds the largest share in the North America region. According to the American Cancer Society, approximately 1,735,350 new cancer cases were diagnosed in the United States in 2018 and there were around 609,640 deaths during the same year. The National Institute of Neurological Disorders and Stroke is mainly focusing on approaches that could facilitate the discovery and validation of robust biomarkers, primarily for better diagnosis and treatment of certain conditions. Hence, with the rising concerns regarding neurological disorders and increasing spending on R&D of novel biomarkers, the market is expected to grow over the forecast period.
To understand geography trends, Download Sample Report.
The global players in the central nervous system biomarkers market are - Acumen Pharmaceuticals Inc., Alseres Pharmaceuticals Inc., Aposense Ltd., Avacta Life Sciences Limited, Banyan Biomarkers Inc., Bio-Rad Laboratories, Inc., DiaGenic ASA, G-Biosciences, Merck KGaA and Thermo Fisher Scientific Inc.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in the Development in Proteomics, Genomics and Imaging System
4.2.2 Rising Investments from Government and Private Players
4.2.3 Increasing Research and Development with Successful Clinical Trials of Biomarkers
4.3 Market Restraints
4.3.1 High Cost of CNS Biomarkers Tests and Diagnostics
4.3.2 Reimbursement and Regulatory Issues
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Type of CNS Biomarkers
5.1.1 Safety Biomarker
5.1.2 Efficacy Biomarker
5.1.3 Validation Biomarker
5.2 By Application
5.2.1 Drug Discovery & Development
5.2.2 Personalized Medicine
5.3 By End User
5.3.1 Diagnostic Labs
5.3.3 Research Centers
5.4.1 North America
188.8.131.52 United States
184.108.40.206 United Kingdom
220.127.116.11 Rest of Europe
18.104.22.168 South Korea
22.214.171.124 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
126.96.36.199 South Africa
188.8.131.52 Rest of Middle-East and Africa
5.4.5 South America
184.108.40.206 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Acumen Pharmaceuticals Inc.
6.1.2 Alseres Pharmaceuticals Inc.
6.1.3 Aposense Ltd.
6.1.4 Avacta Life Sciences Limited
6.1.5 Banyan Biomarkers Inc.
6.1.6 Bio-Rad Laboratories, Inc.
6.1.7 DiaGenic ASA
6.1.9 Merck KGaA
6.1.10 Thermo Fisher Scientific Inc.
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments